日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.

在骨髓增生性肿瘤的临床前模型中,SHP2 抑制剂作为单一疗法以及与 JAK2 抑制剂联合使用均显示出疗效

Pandey Garima, Mazzacurati Lucia, Rowsell Tegan M, Horvat Nathan P, Amin Narmin E, Zhang Guolin, Akuffo Afua A, Colin-Leitzinger Christelle M, Haura Eric B, Kuykendall Andrew T, Zhang Ling, Epling-Burnette Pearlie K, Reuther Gary W

Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience

苯达莫司汀联合利妥昔单抗一线治疗结外边缘区淋巴瘤:单中心经验

Logothetis, Constantine N; Horvat, Nathan P; Kurian, Tony; Bello, Celeste; Chavez, Julio; Isenalumhe, Leidy; Shah, Bijal; Sokol, Lubomir; Saeed, Hayder; Pinilla, Javier; Gaballa, Sameh

HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms

HDAC11 缺陷会破坏骨髓增生性肿瘤中癌基因诱导的造血作用

Yue, Lanzhu; Sharma, Vasundhara; Horvat, Nathan P; Akuffo, Afua A; Beatty, Matthew S; Murdun, Cem; Colin, Christelle; Billington, Julia M R; Goodheart, William E; Sahakian, Eva; Zhang, Ling; Powers, John J; Amin, Narmin E; Lambert-Showers, Que T; Darville, Lancia N; Pinilla-Ibarz, Javier; Reuther, Gary W; Wright, Kenneth L; Conti, Chiara; Lee, Jennifer Y; Zheng, Xiaozhang; Ng, Pui Yee; Martin, Matthew W; Marshall, C Gary; Koomen, John M; Levine, Ross L; Verma, Amit; Grimes, H Leighton; Sotomayor, Eduardo M; Shao, Zonghong; Epling-Burnette, Pearlie K

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis

寻找JAK抑制剂的良方:评估骨髓纤维化中JAK抑制剂联合治疗的过去、现在和未来策略

Kuykendall, Andrew T; Horvat, Nathan P; Pandey, Garima; Komrokji, Rami; Reuther, Gary W